TY - JOUR
T1 - Proficiency test of SARS-CoV-2 Omicron variant detection in diagnostics samples by veterinary diagnostic laboratories
AU - Singh, Neha
AU - Miller, Megan R.
AU - Nemser, Sarah M.
AU - Tkachenko, Andriy
AU - Uhlig, Steffen
AU - Frost, Kirstin
AU - Hettwer, Karina
AU - Ulaszek, Jodie
AU - Kmet, Matthew
AU - Wang, Leyi
AU - Allender, Matthew C.
AU - Reddy, Ravinder
N1 - This study was funded by the FDA Vet-LIRN program, and laboratories were not charged to participate in this exercise. Vet-LIRN laboratories may have used infrastructure grant funds provided via Vet-LIRN funding opportunity PAR-17-141 or PAR-22-063 to cover the cost of supplies.
We acknowledge diligence and hard work of the laboratory scientists who participated in this collaborative study. We acknowledge the following individuals for technical assistance and administrative support: Angelica Jones from the FDA, Hon S. Ip from USGS, and Mary Lea Killian from USDA/APHIS. We thank Gregory Tyson and Laura B. Goodman for review and support during this COVID PT. Laura B. Goodman also provided the equine CoV and assisted with copy number quantification. We also thank Leyi Wang from the University of Illinois for his work to collect, test, and prepare the feline fecal matrix needed for this study.
PY - 2025/2
Y1 - 2025/2
N2 - Veterinary diagnostic laboratories (VDLs) play a critical role in screening both human and animal samples for SARS-CoV-2. To evaluate the SARS-CoV-2 detection methods used by VDLs, a proficiency test was performed by the US Food and Drug Administration’s Veterinary Laboratory and Investigation and Response Network in collaboration with two other organizations. Thirty-two sets of 12 blind-coded samples were prepared by fortifying Molecular Transport Medium (MTM) or feline feces with SARS-CoV-2 Omicron variant or non-SARS-CoV-2 equine coronavirus RNA at various concentrations and shipped to 32 participants for blinded (unbiased) analysis. Results were analyzed according to the principles of International Organization for Standardization 16140-2:2016 using two approaches such as establishing the rate of detection (ROD) and the success rate by applying the analysis of binary outcome by logit approach. ROD provided the overall assessment of laboratories performance, whereas the novel logit approach provided an insight to more specific analysis based on the complexity of each sample. The ROD was 83% and 98% for MTM samples at 200 and 20000 genome copies per 100 µL, respectively. Fecal samples were classified as challenging exploratory, and results were not included in the assessment of performance but discussion purposes only. Fecal samples exhibited matrix interference impacting the performance. The ROD was 44% and 89% for fecal samples at 2000 and 20000 genome copies per 100 µL, respectively. The non-COVID coronavirus RNA, which was used to address the specificity, did not interfere with methods used. Establishing the success rate by evaluating the qualitative results (detected/not detected) applying a logit approach revealed that, out of thirty-two participants, twenty-eight had satisfactory results, one participant had unsatisfactory results, and three participants had questionable results for MTM samples. For fecal samples, three participants out of thirty-two did not meet the expectations at higher concentrations. Lower concentrations of fecal samples were excluded from this analysis. Again, the fecal samples were considered as challenge samples and the results were provided to assist participants in their continuous efforts to improve their performance and not to evaluate their performance.
AB - Veterinary diagnostic laboratories (VDLs) play a critical role in screening both human and animal samples for SARS-CoV-2. To evaluate the SARS-CoV-2 detection methods used by VDLs, a proficiency test was performed by the US Food and Drug Administration’s Veterinary Laboratory and Investigation and Response Network in collaboration with two other organizations. Thirty-two sets of 12 blind-coded samples were prepared by fortifying Molecular Transport Medium (MTM) or feline feces with SARS-CoV-2 Omicron variant or non-SARS-CoV-2 equine coronavirus RNA at various concentrations and shipped to 32 participants for blinded (unbiased) analysis. Results were analyzed according to the principles of International Organization for Standardization 16140-2:2016 using two approaches such as establishing the rate of detection (ROD) and the success rate by applying the analysis of binary outcome by logit approach. ROD provided the overall assessment of laboratories performance, whereas the novel logit approach provided an insight to more specific analysis based on the complexity of each sample. The ROD was 83% and 98% for MTM samples at 200 and 20000 genome copies per 100 µL, respectively. Fecal samples were classified as challenging exploratory, and results were not included in the assessment of performance but discussion purposes only. Fecal samples exhibited matrix interference impacting the performance. The ROD was 44% and 89% for fecal samples at 2000 and 20000 genome copies per 100 µL, respectively. The non-COVID coronavirus RNA, which was used to address the specificity, did not interfere with methods used. Establishing the success rate by evaluating the qualitative results (detected/not detected) applying a logit approach revealed that, out of thirty-two participants, twenty-eight had satisfactory results, one participant had unsatisfactory results, and three participants had questionable results for MTM samples. For fecal samples, three participants out of thirty-two did not meet the expectations at higher concentrations. Lower concentrations of fecal samples were excluded from this analysis. Again, the fecal samples were considered as challenge samples and the results were provided to assist participants in their continuous efforts to improve their performance and not to evaluate their performance.
KW - Fecal matrix
KW - Logit approach
KW - Proficiency exercise
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85207001981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85207001981&partnerID=8YFLogxK
U2 - 10.1007/s00769-024-01622-w
DO - 10.1007/s00769-024-01622-w
M3 - Article
SN - 0949-1775
VL - 30
SP - 45
EP - 53
JO - Accreditation and Quality Assurance
JF - Accreditation and Quality Assurance
IS - 1
ER -